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Abstract
Epigenetics is the term used to describe heritable changes in gene expression that are not coded
in the DNA sequence itself but by post-translational modifications in DNA and histone proteins.
These modifications include histone acetylation, methylation, ubiquitination, sumoylation and
phosphorylation. Epigenetic regulation is not only critical for generating diversity of cell types
during mammalian development, but it is also important for maintaining the stability and integrity
of the expression profiles of different cell types. Until recently, the study of human disease has
focused on genetic mechanisms rather than on non-coding events. However, it is becoming
increasingly clear that disruption of epigenetic processes can lead to several major pathologies,
including cancer, syndromes involving chromosomal instabilities, and mental retardation.
Furthermore, the expression and activity of enzymes that regulate these epigenetic modifications
have been reported to be abnormal in the airways of patients with respiratory disease. The
development of new diagnostic tools might reveal other diseases that are caused by epigenetic
alterations. These changes, despite being heritable and stably maintained, are also potentially
reversible and there is scope for the development of 'epigenetic therapies' for disease.
Introduction
The genetic code cannot be the sole arbiter of cell fate
since each cell in a blastocyst can differentiate into the
many different cell types found in multicellular organisms
each with a unique function and gene expression pattern.
This has led to the idea that additional information
beyond that generated by the genetic code must be impor-
tant for the regulation of genomic expression. Over 60
years ago the term "epigenetics" was introduced to
describe this information and this is now understood to
mean all meiotically and mitotically heritable changes in
gene expression that are not coded in the DNA sequence
itself [1]. Epigenetic regulation is not only critical for gen-
erating diversity of cell types during mammalian develop-
ment, but it is also important for maintaining the stability
and integrity of the expression profiles of different cell
types. Interestingly, whereas these epigenetic changes are
heritable and normally stably maintained, they are also
potentially reversible, as evidenced by the success of clon-
ing entire organisms by nuclear transfer methods using
nuclei of differentiated cells [2]. Therefore, understanding
the basic mechanisms that mediate epigenetic regulation
is invaluable to our knowledge of cellular differentiation
and genome programming.
Studies of the molecular basis of epigenetics have largely
focused on mechanisms such as DNA methylation and
chromatin modifications [3]. In fact, emerging evidence
indicates that both mechanisms act in concert to provide
stable and heritable silencing in higher eukaryotic
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genomes. Interestingly, the recently described process of
RNA silencing, originally utilised by the cell to protect
itself against viral infection, also involves the same mech-
anisms used to sustain epigenetic silencing. These compo-
nents (DNA methylation, chromatin modifications and
RNA-associated silencing) interact and often disruption of
one component will affect the activity/expression of the
other two leading to inappropriate expression or silencing
of genes, resulting in 'epigenetic diseases' [1,3].
It is possible for epigenetic marks to be transmitted along
chromosomes. Drosophila and plants exhibit a characteris-
tic known as position-effect variegation (PEV) whereby
euchromatic genes can become transcriptionally silenced
when juxtaposed to heterochromatic sequences [1]. The
extent of this cis-spreading silencing phenomenon varies
and involves a number of proteins which have roles in
heterochromatin formation e.g. E(var)s (enhancers of
PEV) or Su(var)s (suppressors of PEV) [4]. Su(var) 2–5 for
example encodes the chromatin-binding nuclear protein
heterochromatin protein 1 (HP1) [5] which has a critical
role in initiating and maintaining the condensed chroma-
tin conformation of heterochromatin through its actions
on histone methylation and chromatin remodelling.
Epigenetic marks
DNA methylation
One of the most fundamental epigenetic marks is the
widespread methylation of the C5 position of cytosine res-
idues in DNA [1,6]. The maintenance of these methyl
CpG marks is due to the action of a number of DNA meth-
yltransferases (DNMTs) which add the universal methyl
donor S-adenosyl-L-methionine to cytosine (Table 1).
These enzymes have been implicated in many processes
including transcriptional regulation, genomic stability,
chromatin structure modulation, X chromosome inactiva-
tion, and the silencing of parasitic DNA transposable ele-
ments [7]. Overall, DNA methylation exerts a stabilizing
effect which promotes genomic integrity and ensures
proper temporal and spatial gene expression during devel-
opment. In contrast, DNA demethylation is probably a
passive event and no bona fide DNA demthylase has been
identified to-date [8]. The importance of DNA methyla-
tion is highlighted by the fact that many human disease
result from abnormal control [9]. In addition, cytosine
methylation is highly mutagenic, causing a C to T muta-
tion resulting in loss of the CpG methyl-acceptor site, and
aberrant methylation of CpG islands is a characteristic of
many human cancers and may be found in early carcino-
genesis [3,10,11].
It has been estimated that as much as 80% of all CpG
dinucleotides in the mammalian genome are methylated
[1]. The remaining unmethylated CpG residues are mostly
located in the promoter regions of constitutively active
and/or inducible genes and are referred to as CpG islands.
CpG islands generally consist of regions of >500 base
pairs with a GC content greater than 55% [9,12]. When
methylated these CpG islands result in stable inherited
transcriptional silencing. How sequences are targeted for
de novo methylation in mammals remains largely
unknown. Several triggers have been proposed to target
DNA methylation including: (i) sequence, composition
or secondary structure of the DNA itself; (ii) RNAs that
might target regions on the basis of sequence homology;
and (iii) specific chromatin proteins, histone modifica-
tions or higher-order chromatin structures and these are
clearly not mutually exclusive [13].
Early models for the control of DNA methylation pro-
posed two-steps: 'de novo methylation' by DNMTs active
on unmethylated DNA e.g. DNMT3a and 3b [14], fol-
lowed by 'maintenance methylation' by DNMT3a or by
DNMT1 which is specific for the hemi-methylated DNA
Table 1: DNA methyltransferases (DNMTs) and methyl binding proteins. Dnmts establish and maintain methylation marks whilst 
methyl CpG binding proteins interpret these marks.
DNA methyltransferase Activity Function
DNMT1 Prefers hemi-methylated DNA Maintenance of methylation, repression of 
transcription
DNMT2 Low activity in vitro Non CpG methylation in Drosphilia
DNMT3a De novo methylation Imprinting and repression
DNMT3b De novo and maintenance methylation Repeat methylation, repression
DNMT3L Not active, co-localizes with DNMT3a and 3b Repeat methylation, repression
Methyl CpG binding protein Specificity
MeCP2 Single methylated CpG Repression
MBD1 Methylated and unmethylated DNA Repression
MBD2 Methylated DNA Repression
MBD3 Unmethylated DNA Repression
MBD4 5-meCpG/TpG mismatches DNA repair,
Abbreviations: MeCP – Methyl-CpG-binding protein, MBD – methyl-CpG binding domain.Respiratory Research 2006, 7:21 http://respiratory-research.com/content/7/1/21
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resulting from replication [15]. However, the validity of
this model has recently been questioned [9]. There are a
number of DNMTs and DNMT-interacting proteins
reported mostly distinguished on the basis of structural
similarity, sequence specificity but rarely primary func-
tion. Indeed most predicted proteins have been desig-
nated as being DNMTs solely because they have most, or
all, of the conserved motifs observed in the catalytic
domain of known DNMTs [9,10]. The problem is com-
pounded by the fact that DNMTs may also form com-
plexes with each other [16].
Mammalian Dnmt1 is considered to be a maintenance
DNMT as knockout studies and antisense approaches
show a global effect on methylation [9,17]. Furthermore,
DIM-2, a relative of Dnmt1, is responsible for all known
DNA methylation in Neurospora  [13]. Some potential
DNMTs include proteins for which little or no enzymatic
activity has been found in mammalian cells [13], thus,
mammalian DNMT2 has little or no DNMT activity in
vitro [18], and deletion of Dnmt2 in mouse embryonic
stem cells had no noticeable effect on DNA methylation
[13]. In contrast, depletion of Drosophila Dnmt2 by RNAi,
however, resulted in loss of the little DNA methylation
detectable by immunolocalization, and overexpression
appeared to induce hypermethylation [19].
DNA methylation can repress transcription through sev-
eral mechanisms including direct inhibition of transcrip-
tion factor DNA binding and indirectly through the effects
of methyl CpG binding proteins (Table 1). As such,
methyl-CpG binding proteins e.g. MeCP2 and MBDs are
recruited to methylated CpG where they can act as media-
tors of transcriptional repression through the association
with HDAC containing repressor complexes. Interest-
ingly, Mbd2 knockout cells can express IL-4 in cells where
this gene is normally silent [20]. In contrast, CpG methyl-
ation blocks DNA binding of the chromatin boundary ele-
ment binding protein (CTCF), which can block
interactions between an enhancer and its promoter when
placed between the two elements resulting in gene induc-
tion. Generally loss of MBDs is less profound than that of
DNMT loss since DNMTs greatly reduce the extent of
genomic DNA methylation and therefore interfere with all
proteins that interpret the DNA methylation signal
whereas loss of one methyl-CpG binding protein will ena-
ble other proteins that recognize the DNA methylation
signal.
DNA methylation, in conjunction with post-translational
modifications of histones, is involved in the regulation of
chromatin states that are either mutually reinforcing or
mutually inhibitory possibly acting through feedback
loops [17]. This may polarize chromatin, committing it to
enable either transcriptional activity or transcriptional
silence with uncommitted states being rare. This would
imply that an active mechanism must be involved in
switching between transcriptionally active and silenced
states. Recently, clear evidence for cross-talk between
these epigenetic processes has been provided. Thus, the
polycomb group (PcG) protein EZH2 (Enhancer of Zeste
homolog 2) serves as a recruitment platform for DNMTs
indicating a direct link between the two major epigenetic
repression systems [21]. Similarly, histone H1 depletion
induced marked changes in chromatin structure such as
decreasing global nucleosome spacing and reducing local
chromatin compaction without affecting global DNA
methylation. However, many of the genes whose expres-
sion was regulated by H1 depletion showed evidence for
reduced methylation of specific CpGs within their regula-
tory regions thereby suggesting that linker histones can
also play a role in the maintenance or establishment of
specific DNA methylation patterns [22].
Chromatin structure and histone modifications
Chromatin is made up of nucleosomes which are particles
consisting of 146 bp of DNA wrapped around an octomer
of two molecules each of the core histone proteins (H2A,
Heterochromatin is the compacted "closed" form of chroma- tin associated with gene silencing Figure 1
Heterochromatin is the compacted "closed" form of chroma-
tin associated with gene silencing. Activation of chromatin to 
its more "open" form which allows gene expression to occur 
is regulated by modification of core histones by specific co-
activator complexes containing enzymes which can acetylate, 
phosphorylate or methylate histone tails. Removal of the 
linker histone H1 and changes in DNA methylation state are 
also important in this process. This is reversed by corepres-
sor complexes that include histone deacetylases (HDACs) 
and both DNA and histone methylases, thereby causing gene 
silencing.Respiratory Research 2006, 7:21 http://respiratory-research.com/content/7/1/21
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H2B, H4 and H4). Nucleosomal DNA can be further com-
pacted by association with the linker histone H1 and addi-
tional nonhistone proteins, as well as by higher order
looping and folding of the chromatin fibre. In the resting
cell DNA is wound tightly around these basic core his-
tones, presenting an impenetrable barrier to large protein
complexes such as RNA polymerase II, which produce
unspliced primary messenger RNA transcripts. Alterations
in the structure of chromatin are critical to the regulation
of gene expression [1,23,24].
Over 100 years ago cytologists appreciated the link
between chromatin compaction and cell activation status.
Thus chromatin was divided into two major forms: hete-
rochromatin and euchromatin [1]. Heterochromatin was
defined as condensed regions of the nucleus that do not
decondense during interphase, whereas euchromatin was
noted to readily decondense upon exit of mitosis. It was
postulated that heterochromatin is the functionally inac-
tive regions of the genome and euchromatin is where gene
activity occurs (Figure 1). We now know that heterochro-
matin regions less susceptible to nuclease activity; contain
few actively expressed genes, and replicate late in the S-
phase [1,25]. In contrast, euchromatin is more open and
accessible to nucleases, is rich in actively transcribing
genes, and replicates early during S-phase [1,25].
Allfrey and colleagues [26] initially described a role for
histone acetylation in de novo mRNA synthesis in 1964
however it wasn't until the mid 1990s that a molecular
appreciation of the events linking histone acetylation and
gene expression were made. In these later studies it was
reported that transcriptional co-activator proteins act as
the molecular switches that control gene transcription and
all have intrinsic histone acetyltransferase (HAT) activity
[27,28]. Gene transcription occurs when the chromatin
structure is opened up, with loosening of the tight nucle-
osomal structure allowing RNA polymerase II and basal
transcription complexes to interact with DNA and initiate
transcription. When transcription factors are activated
they bind to specific recognition sequences in DNA and
subsequently recruit large coactivator proteins, such as
cAMP-response element binding protein (CREB)-binding
protein (CBP), p300 and PCAF (p300-CBP associated fac-
tor) and other complexes to the site of gene expression
[23].
The N-terminal tails of the histone molecules protrude
through and beyond the DNA coil presenting accessible
targets for post-translational modifications such as
acetylation, phosphorylation, methylation, sumoylation
and ubiquitination of selective amino acid residues (Fig-
ure 2). Some modifications, including acetylation and
phosphorylation, are reversible and dynamic and are
often associated with inducible expression of individual
genes. Thus, lysine residues in the tails of histone H3 and
H4 may be acetylated forming bromodomains enabling
the association of other co-activators such as TATA box
binding protein (TBP), TBP-associated factors, chromatin
modifying engines and RNA polymerase II [23,28](Figure
3). This molecular mechanism is common to all genes,
including those involved in differentiation, proliferation
and activation of cells. Just as acetylation of histones is
associated with gene induction, removal of acetyl groups
by histone deacetylases (HDAC)s is generally associated
with re-packing of chromatin and a lack of gene expres-
sion or gene silencing [29]. Other modifications, such as
methylation, are generally more stable and are involved in
the long-term maintenance of expression status. Since
these modifications occur on multiple but specific sites it
has been suggested that modified histones can act as sig-
nalling templates, integrating upstream signalling path-
ways to elicit appropriate nuclear responses such as
transcription activation or repression [30]. The Histone
Code Hypothesis proposes that different combinations of
histone modifications may result in distinct outcomes in
terms of chromatin-regulated functions [31].
Histone acetylation
Recruitment of a histone modifying enzyme to the right
place at the right time is only the first step in establishing
a combination of histone marks that may direct a biolog-
ical outcome. The second step in this process revolves
around the specificity of the enzyme for individual his-
tone tails and for specific histone residues [23]. For exam-
ple, Gcn5 (general control non-derepressible 5) and PCAF
preferentially acetylate H3 K9 and K14 whereas NuA4
HAT complexes preferentially acetylate K4, K8, K12 and
K16 of histone H4 [32] (Table 1).
It was originally proposed that histone acetylation would
alter the electrostatic interaction between histones and
DNA by altering the charge on the lysine residue leading
to an "open" structure. However, at best, full acetylation
of histone H3 is likely to lead to a 10–30% decrease in
positive charge which is unlikely to affect interactions
with DNA [32]. The major role of acetylated histones is to
direct the binding of nonhistone proteins. For example,
bromodomains specify binding to acetylated lysines but
this does not show much specificity. For instance, acetyla-
tion of K8 within histone H4 can promote the recruitment
of the ATP-dependent chromatin remodeling enzyme,
human SWI/SNF – via a bromodomain within the Brg1
subunit – but a similar bromodomain within the Swi2
subunit of the yeast SWI/SNF complex interacts with a
broader range of acetylated H3 and H4 tails [32,33]. Thus,
the major role of the bromodomain, and the chromodo-
main (see later), is to serve as the nidus for assembly of co-
activator vs. co-repressor complexes (Figure 3).Respiratory Research 2006, 7:21 http://respiratory-research.com/content/7/1/21
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HATs are divided into five families. These include the
Gcn5 (general control non-derepressible 5)-related acetyl-
transferases (GNATs); the MYST (for 'MOZ, Ybf2/Sas3,
Sas2 and Tip60)-related HATs; p300/CBP HATs; the gen-
eral transcription factor HATs, which include the TFIID
subunit TAF250 (TBP-associated factor of 250 kDa); and
the nuclear hormone-related HATs SRC1 (steroid receptor
coactivator 1) and ACTR (activator of retinoid receptor)
[34]. In addition to these three major groups of HATs,
more than a dozen other proteins have been shown to
possess acetyltransferase activity [34].
Most HATs exist as stoichiometric multisubunit com-
plexes in vivo [35]. The complexes are typically more active
than their respective catalytic subunits and display distinct
substrate specificities [36,37], suggesting that associated
subunits regulate the activities of the respective catalytic
subunits. In addition, non-catalytic subunits are also
involved in recruiting substrates for targeted action to
ensure the specificity. One HAT can be the catalytic subu-
nit of multiple complexes thus, GCN5L forms at least two
distinct multisubunit complexes [35], and yeast Gcn5 is
the catalytic subunit of four complexes [34]. Increasingly
levels of complexity are being found e.g. recent studies
indicate that Ubp8, a deubiquitinating enzyme present in
two Gcn5 complexes, controls the deubiquitination of
histone H2B and methylation of histone H3 [38]. Incor-
poration of HATs into complexes also alters lysine specif-
icity. On free histones Gcn5 alone acetylates mainly H3
lysine 14, SAGA acetylates lysines 9, 14, 18 and 23, and
ADA acetylates 9, 14 and 18 [35,39]. Thus, HAT complexe
subunits not only specify histone modification, but also
transcriptional function in targeting of these complexes to
promoters.
Histone deacetylases
HDACs play a critical role in reversing the hyperacetyla-
tion of core histones. Lysine acetylation is reversible and
is controlled by the opposing actions of HATs and HDACs
in vivo (Figure 4). Since histones were thought to be the
major cellular proteins modified by lysine acetylation,
most lysine HATs and HDACs were initially identified as
histone acetyltransferases and HDACs [23,40].
HDACs are divided into four classes: I (HDAC1, -2, -3,
and -8), II (HDAC4, -5, -6, -7, -9, and -10), III (Sirt1, -2, -
3, -4, -5, -6, and -7) and IV (HDAC11) [41-43]. The widely
expressed class I HDACs are exclusively localized to the
nucleus whereas the more restricted class II HDACs shut-
tle between the nucleus and cytoplasm (Table 2). There is
evidence that these different HDACs target different pat-
terns of acetylation and regulate different genes [40]. The
different HDACs are also likely to be regulated differently.
HDACs interact with corepressor molecules, such as
nuclear receptor corepressor (NCoR), ligand-dependent
corepressor (LCoR), NuRD (nucleosomes remodelling
and decatylase) and mSin3 (Switch independent 3), all of
which aid HDACs in gene repression and may provide
specificity by selecting which genes are switched off by
HDAC [41,44,45] (Figure 5).
The activities of most if not all HDACs are regulated by
protein-protein interactions. In addition, many HDACs
are regulated by post-translational modifications as well
as by subcellular localization. HDACs generally exist as a
component of stable large multi-subunit complexes, and
most, if not all, HDACs interact with other cellular pro-
teins. With the exception of mammalian HDAC8, most
purified recombinant HDACs are enzymatically inactive
[46]. Any protein that associates with HDACs, therefore,
has the potential to activate or inhibit the enzymatic activ-
ity of HDACs. Likewise, HDACs, in general, have no DNA
binding activity, therefore, any DNA-binding protein that
targets HDACs to DNA or to histones potentially can
affect HDAC function.
Human HDAC1 and HDAC2 exist together in at least
three distinct multi-protein complexes called the Sin3, the
NuRD, and the Co-repressor of REST (RE1 silencing tran-
scription factor, CoREST) complexes [46](Figure 5). Sin3
and NuRD complexes share a core comprised of four pro-
teins: HDAC1, HDAC2, retinoblastoma associated pro-
tein (RbAp)46, and RbAp48. In addition, each complex
Epigenetic modifications within the nucleosomes Figure 2
Epigenetic modifications within the nucleosomes. A number 
of distinct post-translational modifications including acetyla-
tion (orange flag), phosphorylation (red circle), ubiquitination 
(blue star) and methylation (green flag) occur at the N ter-
mini of histones H2A, H2B, H3 and H4. Other modifications 
are known and may also occur in the globular domain. Meth-
ylation of C5 on cytosine residues within CpG regions of 
DNA are also important markers for epigenetic effects. The 
histones are depicted in single-letter amino-acid code with 
the residue number shown underneath.Respiratory Research 2006, 7:21 http://respiratory-research.com/content/7/1/21
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contains unique polypeptides (Sin3, sin3 associated pro-
tein (SAP)18, and SAP30 in the Sin3 complex; Mi2,
metastasis-associated gene family (MTA)-2, and methyl
CpG binding domain (MBD)3 in the NuRD complex)
which are essential for HDAC activity and function
[47,48]. Thus the NuRD complex may link acetylation
and methylation in the regulation of gene expression [46].
Similar results are seen for HDAC activity within the CoR-
EST complex [49]. Furthermore, HDAC3 activity is
dependent upon silencing mediator of retinoid and thy-
roid receptor (SMRT) and nuclear receptor corepressor
(N-CoR) association [46].
Unlike HDAC3, the class II HDACs cannot be activated by
SMRT/N-CoR alone. Instead, the enzymatic activity of
HDAC4, 5, and 7 is dependent on the association with the
HDAC3/SMRT/N-CoR complex [46]. These studies sug-
gest that HDAC4, 5, and 7 are not active deacetylases but
recruit preexisting enzymatically active SMRT/N-CoR
complexes containing HDAC3 [50] (Figure 5).
All mammalian HDACs possess potential phosphoryla-
tion sites and many of them have been found to be phos-
phorylated in vitro and in vivo. HDAC1 phosphorylation
may either alter its conformation into a more favourable
enzymatic active form or affect the ability of HDAC1 to
interact with proteins, such as MTA2 and SDS3, which can
subsequently stimulate its activity and consequently
enhance its enzymatic activity [46]. Similarly, HDAC2
phosphorylation is necessary for both enzymatic activity
and association with the corepressors mSin3 and Mi2
[46]. The activity of class II HDACs may also be regulated
by phosphorylation via modulating their subcellular
localization [46]. HDACs must reside in the nucleus in
order to deacetylate histones and to repress transcription,
therefore, signals that enhance HDAC nuclear localization
must affect HDAC activity. HDAC1, 2, and 8 are predom-
inantly nuclear proteins but in contrast, HDAC3 can be
found both in the nucleus and cytoplasm and the nuclear/
cytoplasmic ratio depends on cell types and stimuli [46].
Thus, in response to IL-1β stimulation, the N-CoR/TAB2/
HDAC3 corepressor complex undergoes nuclear to cyto-
plasmic translocation, resulting in derepression of a spe-
cific subset of NF-κB-regulated genes [51].
In contrast, experiments in cardiac myocytes shows that
class II HDACs shuttle between the nucleus and the cyto-
plasm where they associate with 14-3-3 proteins [52,53].
The binding of class II HDACs to 14-3-3 is absolutely
dependent on phosphorylation of conserved N-terminal
serine residues and this association results in sequestra-
tion of HDACs to the cytoplasm [52,53]. Furthermore,
CaMK-mediated phosphorylation of HDACs 4, 5, 7, and
9 promotes their association with 14-3-3 proteins result-
ing in increased retention of HDACs in the cytoplasm.
Binding of 14-3-3 has been suggested to mask an N-termi-
nal nuclear localization signal [52,53].
Interestingly, HDACs can autoregulate their own expres-
sion by feedback mechanisms utilising the DNA binding
actions of transcription factors such as NF-Y (nuclear fac-
tor Y) and Sp1. Furthermore, some degree of cross-talk in
this regulation must also occur as changes in HDAC1
expression can also affect the expression of other class I
HDACs [46]. Recent evidence [54] has shown that nitra-
tion of HDAC2 can lead to protein degradation. Proteaso-
mal degradation appears to be a major mechanism of
regulation of HDAC function [46].
Histone methylation
Histone methylation has been implicated for over 40
years in the control of gene expression [26]. Histones may
be methylated on either lysine (K) or arginine (R) resi-
dues. Due to their small size and their charged nature it is
unlikely that these marks alter chromatin structure. It is
therefore believed that methylation of K or R residues
Histone modifications act by serving as a node for the assem- bly of coactivators and corepressor complexes through the  recognition of these modifications by proteins that contain  bromodomains (recognize acetylated lysines) or chromodo- mains (recognize methylated lysines) Figure 3
Histone modifications act by serving as a node for the assem-
bly of coactivators and corepressor complexes through the 
recognition of these modifications by proteins that contain 
bromodomains (recognize acetylated lysines) or chromodo-
mains (recognize methylated lysines). This, rather than an 
effect on chromatin structure per se, determines effects on 
gene expression. Recruitment of heterochromatin protein 
(HP)1 through a chromodomain may also affect local DNA 
methylation through recruitment of DNA methyltransferases 
(DNMTs) and methyl binding domain (MBD) proteins. This 
may lead to further assembly of other histone methyl trans-
ferases (HMTs) and histone deacetylase (HDAC) complexes 
which enable further gene silencing to occur. Gene activa-
tion, in contrast, requires recruitment of an acrivation com-
plex involving the TATA binding protein (TBP) and its 
associated factors (TAFs), chromatin remodeling complexes 
such as mating type switching/sucrose non-fermenting (SWI/
SNF) and RNA polymerase II (RNA pol II).Respiratory Research 2006, 7:21 http://respiratory-research.com/content/7/1/21
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forms a binding site or interacting domain allowing other
regulatory proteins to be recruited. Methyl-K residues may
exist in either the mono-, di- or tri-methylated forms. In
contrast, R methylation may be either mono-methylated
or di-methylated although a further complexity is added
by the ability of di-Me-R to be symmetrical or asymmetri-
cal [30]. Currently, there are at least 17 K and 7 R residues
known to be methylated suggesting a large number of
possible combinations.
Most of our knowledge concerning the role of methyla-
tion in gene expression has come from experiments in
yeast and Drosophila however, general principles appear to
hold true in man [30]. Histone H3 and H4 methylation
has been most studied and distinct forms are presence
within heterochromatin (condensed, heritable and tran-
scriptionally inert chromatin) and euchromatin (loosely
packed and transcriptionally active chromatin). Thus
methylated forms of H3K9, H3K27, H3K79 and H4K20
are found to be associated with heterochromatin whereas
activated genes with euchromatin are associated with
methylated H3K4 and H3K36 histones. Upon selective
gene activation further methylation of these histones
(H3K4 & H3K36) within the 5' controlling regions of
genes occurs [30]. These posttranslational modifications
are carried out by histone methyl-transferases (HMT),
which covalently modify lysines and arginines on his-
tones. These modifications, in combination with acetyla-
tions, are thought to inscribe a histone pattern that
recruits factors that affect transcription [55].
The discovery that one of the well-studied Su(var) genes
encoded a histone methyltransferase (HMT) was a major
breakthrough in the understanding the function of H3K-
methylation [1]. The Drosophila Su(var)3–9 gene was orig-
inally pulled out of a genetic screen for transcriptional
silencing associated with heterochromatin [56]. Subse-
quently, the human homolog, Suv39H1, was shown to
specifically methylate histone H3 at K9 [57]. Structure-
function analyses of Suv39H1 and other HMTs indicated
that the SET domain was responsible for HMT activity.
The highly conserved SET domain is named after three
proteins all with silencing properties: Su(var)3–9,
enhancer of zeste [E(Z)], and trithorax (TRX) [56]. Many
SET domain-containing proteins have high specificity for
different sites on H3 and H4 but it is important to note
that not all SET domain-containing proteins are HMTs,
nor are the activities of all HMTs mediated by SET
domains [1]. For example, Dot1p is a non-SET domain-
containing enzyme that methylates H3 at Lys79 [1,58].
As with acetylation, the functional consequence of his-
tone K methylation depends upon the proteins that recog-
nize the particular modification. Protein that induce gene
repression, such as heterochromatin protein 1 (HP1) (Fig-
ure 3) or the Drosophila Polycomb (PC) protein, contain a
chromodomain that allows them to specifically recognize
the appropriate repressive methylation mark (H3K9 and
H3K27 respectively) [30], whereas the activating protein
chromodomain helicase DNA-binding protein 1 (CHD1)
from Saccharomyces cerevisiae uses its chromodomain to
bind the activating methylated H3K4 [59]. Other
domains, important for the recognition of distinct meth-
ylated lysine residues have also evolved e.g. for the recruit-
ment of proteins involved in DNA repair (see later)
although it is not known generally how recruitment of
distinct proteins to particular methylated lysines leads to
the desired functional effect [30].
Demethylation of lysines
The enzyme LSD1 (lysine-specific demethylase 1) which
is able to demethylate H3K4 has recently been identified
[60]. The ability to target the activating methylated H3K4
site correlates with its expression in a number of repressor
complexes [30]. However, LSD1 can only demethylate the
mono- or di-methylated forms of H3K4 despite the fact
that the tri-methylated state is most closely associated
The histone switch Figure 4
The histone switch. Targeted modifications under the con-
trol of histone methylases (HMTs), histone acetyltransferases 
(HATs) and histone deacetylases (HDACs) alter the histone 
code at gene regulatory regions. This establishes a structure 
that contains bromo- and chromo-domains that permits 
recruitment of ATP-dependent chromatin remodelling fac-
tors to open promoters and allow further recruitment of the 
basal transcription machinery. Deacetylation, frequently fol-
lowed by histone methylation, establishes a base for highly 
repressive structures, such as heterochromatin. Acetylated 
histone tails are shown as yellow stars. Methylation (Me) is 
shown to recruit heterochromatin protein 1 (HP-1).Respiratory Research 2006, 7:21 http://respiratory-research.com/content/7/1/21
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with active genes. This suggests that other enzymes must
exist although the action of co-factors may also be impor-
tant. In addition, it has been reported that the androgen
receptor may be able to alter the specificity of LSD1 from
H3K4 to H3K9, and thereby converts the demethylase
from a repressor to an activator of transcription [61]. This
data is controversial and requires confirmation. The
recent discovery of demethylases has opened up a new
area of research and suggested that methyl marks are not
necessarily permanent. This agrees with evidence from
stem cells and cell lines indicates that patterns of gene
expression thought to be under epigenetic control can be
reversed [2,62].
Arginine methylation and demethylation
There are a number of protein arginine methyltransferases
(PRMTs) and R methylation is only found on chromatin
when genes are actively transcribed particularly in
response to oestrogen receptor activation although a
methyl R binding protein has not been reported [63].
Table 2: HAT and HDAC family members
HDAC families Substrate
Class I (Rpd3 homologs)
HDAC 1 H2A, 2B, 3, 4, AR, ER, SHP, YY1
HDAC 2 H2A, 2B, 3, 4, GR, YY1
HDAC 3 H2A, 2B, 3, 4, GR, SHP, GATA1, YY1
HDAC 8 H2A, 2B, 3, 4
Class II (Hda1 homologs)
HDAC 4 H2A, 2B, 3, 4, GATA1
HDAC 5 H2A, 2B, 3, 4, GATA1
HDAC 6 H2A, 2B, 3, 4, tubulin, SHP
HDAC 7 H2A, 2B, 3, 4
HDAC 9 H2A, 2B, 3, 4
HDAC 10 H2A, 2B, 3, 4
Class III (Sir2 homologs)
SIRT 1
SIRT 2
SIRT 3
SIRT 4 Non-histone proteins
SIRT 5 e.g. tubulin, p65, p53
SIRT 6
SIRT 7
Class IV (Rpd3 homolog)
HDAC 11 H2A/H2B/H3/H4
HAT families
GNATs (Gcn5-related acetyltransferase)
Hat1 H4/H2A
Gcn5 and Gcn5L H3 K9/K14/H2B, c-Myc
Elp3 H3/H4
Hpa2 H3/H4
PCAF H3/H4, c-Myc, GATA2
MYST (MOZ, Ybf2/Sas3, Sas2, Tip60-related)
Esa1 H4/H2A
Tip60 H4/H2A, c-Myc, AR
MOF H4 K16/H3/H2A
MOZ
Sas3 H3/H4
Sas2 H4K16
P300/CBP
P300/CBP H2A/H2B/H3/H4, p53, p65, AR, ER
General transcription factor HATs
TAF250 H3/H4
TFIIIC H2A/H3/H4
Nuclear hormone related HATs
SRC1 H3/H4
SRC3/ACTR H3/H4
For abbreviations used see text.Respiratory Research 2006, 7:21 http://respiratory-research.com/content/7/1/21
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Interestingly, during oestrogen-mediated gene induction,
H3R2 methylation appears to be transient or even cyclical
[64] which suggest the existence of enzymes that reverse R
methylation. Recently, an enzyme peptidyl arginine deim-
inase 4 (PADI4) has been found which removes the
methyl group mono-methyl R residues in H3 and H4
[65,66]. PAD14 converts the R residue to citrulline but
whether citrulline can be removed or converted back to R
is unknown as is the answer to the question as to whether
citrulline itself can act as an epigenetic mark. Interestingly,
PAD14 activity is linked to the repression of an oestrogen-
controlled gene, pS2 [30].
Cross-talk between histone marks
Cross-talk between different histone marks can also have
a profound effect on enzyme activity [1]. For instance,
ubiquitylation of H2B K123 by the E2 ubiquitin conjugat-
ing enzyme Rad6 is required for subsequent di-methyla-
tion of H3 K4 by Set1p or H3 K79 by Dot1p [38]. Prior
histone marks can also inhibit subsequent modifications
[1]. For example, H3 S10 phosphorylation inhibits subse-
quent H3 K9 methylation, and of course H3 K9 methyla-
tion can also block acetylation of this same residue. More
recently it has been demonstrated that S10 phosphoryla-
tion by Aurora B kinase can lead to the dissociation of
HP1 from heterochromatin without affecting K9 methyl-
ation status [67,68]. An excellent example of even more
complex cross-talk is exemplified during p53-dependent
transcriptional activation in vitro [69]. In this case methyl-
ation of H4 R3 by PRMT1 stimulates CBP-p300 acetyla-
tion of H4 K5, K8, K12 and K16, which in turn promotes
the methylation of H3 R2, R17 and R26 by another PRMT
family member, CARM1. Thus, positive and negative
crosstalk ultimately generates the complex patterns of
gene or locus-specific histone marks associated with dis-
tinct chromatin states.
Histone variants
Chromatin arrays also contain novel types of nucleosome
that harbour one or more variant isoforms of the core his-
tones [1]. For instance, nucleosomes assembled at yeast
and mammalian centromeres contain a histone H3 vari-
ant, Cse4/CENP-A, which is essential for centromere func-
tion or assembly. Another histone H3 variant, H3.3,
replaces canonical histone H3 during transcription, gener-
ating a mark of the transcription event [1]. Several variants
of histone H2A have also been identified. The macro-H2A
variant is restricted to metazoans and functions in X chro-
mosome inactivation, while H2AZ (also known as H2A.F/
Z or H2AvD) is found in all eukaryotes. Surprisingly,
H2AZ is required for one or more essential roles in chro-
matin structure that cannot be replaced by bona fide his-
tone H2A [70]. In most cases, it is not known how histone
variants alter nucleosome structure or change the folding
properties of nucleosomal arrays [70]. Once a histone var-
iant is targeted to a specific locus, there is the potential for
creation of novel chromatin domains that have distinct
regulatory properties. For instance, the amino-terminal
tail of CENP-A lacks the phosphorylation and acetylation
sites that are normally modified in histone H3 at tran-
scriptionally active regions [71].
Methylation and RNA interference (RNAi)
DNA methylation has long been shown to have a tran-
scriptional silencing function which may reflect the fact
that several HDAC-containing complexes possess methyl-
DNA binding motifs [1]. Furthermore, Suv39H1/2 knock-
out cells from mice have an abnormal pericentric hetero-
chromatin DNA methylation pattern [72]. Mutually
reinforcing relationships between histone modifications
and DNA methylation have been found such as H3-K9
methylation is a prerequisite for DNA methylation and
DNA methylation can also trigger H3-K9 methylation
[1,3,73]. It is likely that both DNA and histone methyla-
tion pathways leave epigenetic marks that are required for
Composition of HDAC repressor complexes Figure 5
Composition of HDAC repressor complexes. HDACs lack 
intrinsic repressor activity and require co-factors for optimal 
HDAC activity. The co-repressor proteins involved in the 
major HDAC complexes NuRD (nucleosome remodeling 
and deacetylase), Sin3 (Switch insensitive 3), Co-REST (Co-
repressor of REST (RE1 silencing transcription factor)) and 
N-CoR and SMRT complexes are shown. NuRD and sin3 
complexes share the retinoblastoma associated protein 
(RbAp)46 and 48 proteins and also contain distinct sets of 
proteins. Abbreviations: Co-REST, Co-repressor of REST 
(RE1 silencing transcription factor); MBD3, Methyl CpG 
binding domain 3; Mi2, Mi2 autoantigen; MTA-2, Metastasis-
associated gene family, member 2; N-CoR, Nuclear receptor 
co-repressor; NuRD, Nucleosome remodelling and 
deacetylating; RbAp46, Retinoblastoma associated protein of 
46 kDa; SAP18, Sin3 associated protein of 18kDa; SDS3, Sup-
pressor of defective silencing 3; Sin3, Switch insensitive 3; 
SMRT, Silencing mediator for retinoid and thyroid receptors; 
ZNF217, Zn finger factor 217 kDa.Respiratory Research 2006, 7:21 http://respiratory-research.com/content/7/1/21
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stable and long-term epigenetic silencing. However, it is
unclear what initiates the recruitment of the different epi-
genetic modifiers to their specific target sequences [1,3].
Since its discovery in 1990 as a means of controlling Petu-
nia colour [74] and the more recent demonstration in
mammalian cells there has been great interest in the
mechanisms by which RNA interference (RNAi) controls
mitotically heritable transcriptional silencing [75,76]. It is
clear that components of the RNAi machinery can exist in
complexes with the chromodomain protein CHP1 which
may enable targeting to specific methyl K residues [75,76].
In addition, deletion of components of the RNAi machin-
ery results in impaired centromere function, a derepres-
sion of transgenes integrated at centromeres, and a loss of
the characteristic H3-K9 methylation and HP1 association
[75,76]. Furthermore, miRNAs and antisense RNAs are
involved in the silencing of some mammalian imprinted
genes [77] and in dosage compensation in mammals
[75,76] suggesting that RNA is able to direct histone mod-
ifications (for example, H3-K9 methylation) and DNA
methylation to specific loci, thereby evoking heritable and
stable silencing [75,76]. Finally, there is a report of a case
of α-thalassaemia showing how antisense transcription
could lead to DNA methylation and stable silencing of the
HBA2 globin gene [78].
Inheritance of epigenetic marks on histones
Little detail concerning the mechanisms for inheritance of
histone modifications is known in contrast to that for the
inheritance of DNA methylation through mitotic cell divi-
sion [1]. Methylated K residues do not have a rapid turn-
over rate and early studies looking at the turnover rate of
histone methylation found that the half-life of the methyl
mark on histones was equal to that of the protein itself
indicating an irreversible modification that persisted
through cell division [79]. In addition, even the highly
dynamic acetyl K modifications are maintained during
mitosis and inheritance of acetylation patterns may be
essential to maintain gene expression profiles through
successive generations [80]. Thus, successful propagation
of histone modification patterns requires a way of copy-
ing/replicating preexisting modifications onto the newly
assembled nucleosomes [1]. During DNA replication, pre-
existing nucleosomes of the parental genome are recycled
and deposited onto the newly generated daughter strands,
and therefore, any stable histone modifications can
potentially be transferred from one generation to the next
[1] (Figure 6).
Parental nuclesomes may divide in a semiconservative
manner whereby the parental histone octamer is split into
H2A-H2B/H3-H4 heterodimers that are then equally seg-
regated onto the two daughter DNA strands [81]. The
nucleosome assembly complex then deposits newly syn-
thesized histones to complete the preexisting half of the
nucleosomes raising the potential to faithfully and
equally transmit histone-associated information from
parent to daughter DNA strands [1,81]. In the DNA meth-
ylation process, copying of the methylation pattern dur-
ing replication is mediated by DNMT1 that preferentially
methylates hemimethylated DNA [1]. A similar mecha-
nism could be invoked for HMTs and HATs whereby
recruitment to selectively modified histone residues may
be afforded by the use of chromo- and bromo-domains
within the enzymes themselves.
Role of epigenetics in DNA damage/repair
Following a double stranded strand break (DSB) DNA
repair processes such as homologous recombination and
single-strand annealing occur and the chromatin adjacent
to this DSB plays a role in the repair and signalling events.
Phosphorylation of the C terminus of histone H2AX (a
variant of histone H2A) is an early event following DNA
damage induced by ionizing radiation or by HO endonu-
clease activity. This is a result of the action of two related
PI3K-like kinases called ATR and ATM [82,83]. Phospho-
rylation of H2AX forms a binding interface that allows
recruitment of cohesions or adaptor proteins to the site of
DSB and subsequent recruitment of the repair machinery
[82,83].
Chromatin remodeling complexes such as NuA4 are also
recruited to DSB via proximal H2AX [83,84] possibly
allowing the access to or processing of DNA by repair pro-
teins. Interestingly, NuA4 also contains histone acetyl-
transferase activity and can acetylate histone H4, which is
important for resistance to DNA-damaging agents [84].
Importantly, abrogation of NuA4 function sensitizes cells
to DSB-inducing agents [83,84].
Other histone modifications such as ubiquitination,
acetylation, and methylation have also been implicated in
the DNA damage checkpoint and repair pathways [82,83].
Despite bulk histone methylation not changing after DNA
damage [85] histone methylation does appear to contrib-
ute to the repair process directly interacting with check-
point adaptor proteins. For example, in mammals, H3-
K79-Me is important for localization of the adaptor pro-
tein 53BP1 [85] and cells deficient in Dot1, the HMT
responsible for lysine 79 methylation, are unable to form
53BP1 foci after DNA damage. However, the process is
more complex as neither chromatin remodelling com-
plexes nor histone modifications are absolutely required
for adaptor proteins to function in the repair of DSB due
to ionizing radiation [82,83].
Epigenetic diseases
Heritable patterns of gene silencing are essential to main-
tain normal development and cell differentiation in man.Respiratory Research 2006, 7:21 http://respiratory-research.com/content/7/1/21
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Many inherited or somatically acquired diseases which
involve learning disorders are associated with chromo-
somal alterations [3]. Examples of these include muta-
tions in the ATRX gene which results in consistent changes
in the pattern of methylation of ribosomal DNA, and frag-
ile X syndrome which occurs when a CGG repeat in the
FMR1 5' untranslated region expands and becomes meth-
ylated [3], causing the gene to be silenced and creating a
visible 'fragile' site on the X chromosome. The gross chro-
mosomal anomalies seen in these diseases points to a cen-
tral role for epigenetic mechanisms in chromosome
architecture. Furthermore, mutations in the DNMT3b
gene causes ICF (immunodeficiency, centromeric region
instability and facial anomalies) syndrome [14,86].
A number of the features of complex diseases that are not
explained by genetics may be explained, at least in part, by
the inheritability, partial stability and reversibility of epi-
genetic regulation [87]. Epigenetic regulation has been
proposed to account for age-of-onset effects, sex effects,
parent-of-origin effects (which are very important in
asthma and COPD), disease fluctuations and might pro-
vide an explanation for the phenotypic discordance often
observed among monozygotic twins (70% for multiple
sclerosis, 30% to 50% for diabetes, and 25% for asthma)
[87,88]. Interestingly, PADI4 polymorphisms have been
associated with rheumatoid arthritis in some, but not all,
populations [89,90]. More recently, global histone modi-
fication patterns have been shown to predict the risk of
prostate cancer recurrence [91].
Epigenetic control of inflammatory gene expression in lung 
and airway cells
Induction of inflammatory genes by nuclear factor κB (NF-κB)
Although numerous different pathways are activated dur-
ing the inflammatory response, nuclear factor kappaB
(NF-κB) is thought to be of paramount importance in
asthmatic inflammation because it is activated by numer-
ous extracellular stimuli including cytokines, such as
tumour necrosis factor-α (TNFα) and interleukin-1β (IL-
1β), viruses and immune challenges [92]. In addition, it is
a major target for glucocorticoids [93]. NF-κB is ubiqui-
tously expressed within cells, and it not only controls
induction of inflammatory genes in its own right but also
enhances the activity of other cell- and signal-specific tran-
scription factors [92,94]. Activation of NF-κB allows it to
translocate into the nucleus where it associates with
sequence specific DNA binding elements in the promoter
region of responsive genes [95].
NF-κB can induce histone acetylation and other histone
modifications in a temporal manner [96,97] leading to
recruitment of other co-activator and remodelling com-
plexes and the induction of inflammatory gene expression
[95]. NF-κB-induced acetylation occurs preferentially on
histone H4, rather than histones 2A, 2B or 3, in epithelial
cells and is directed primarily towards lysine residues 8
and 12 at NF-κB responsive regulatory elements [96]. It is
not known whether modifications on H2A and H2B occur
after NF-κB association/activation. The "histone code"
would suggest that even small changes in histone tail
modifications could have marked structural changes and
allow recruitment of distinct co-activator complexes.
Upon DNA binding, NF-κB recruits a large co-activator
complex that contains the HAT proteins cAMP response
element binding protein (CREB) binding protein (CBP)
and p300/CBP (PCAF), although neither of these are the
major HAT activated by NF-κB [96]. Several other HATs
have been reported to be associated with NF-κB, including
transcriptional intermediary factor-2 (TIF-2), also known
as glucocorticoid receptor interacting protein-1 (GRIP)-1;
p300; and members of the p160 family and steroid recep-
tor coactivator-1 (SRC-1) [98].
Recently it has become apparent that NF-κB activated by
distinct cellular stimuli controls the expression of differ-
ent patterns of genes [99-101] due to differing temporal
profiles of NF-κB activation and nuclear retention. These
results suggest that subtle alterations in NF-κB activation
conditions may have marked effects on co-factor/remod-
elling complex recruitment and subsequent gene induc-
tion. Furthermore, it has also become clear that small
changes in the consensus κB binding site and surrounding
bases can have profound effects on the subsequent ability
of activated NF-κB to activate gene expression [102]. NF-
κB is predominantly composed of the p50/p65 het-
erodimer [92] and subtle changes in p65 phosphorylation
are also influential in regulating NF-κB activity; for exam-
ple, inactive p65 is nonphosphorylated and is associated
predominantly with HDAC1, whereas p65 is phosphor-
ylated following IKK-2 stimulation and is able to bind to
coactivator molecules such as p300/CBP [103].
The histone deacetylase inhibitor trichostatin A has been
reported to enhance NF-κB-driven inflammatory gene
transcription in a number of cell lines [96,103\ensash
105]. Two major mechanisms for this effect have been
proposed. In the first case it has been reported that NF-κB
has an associated HDAC when bound to DNA that acts as
a break on the ability of NF-κB to activate local HAT activ-
ity. Inhibition of this associated HDAC leads to increased
local HAT activity and elevated inflammatory gene tran-
scription [96,103-105]. Warner Greene and colleagues
[105] have proposed an alternative mechanism whereby
HDAC3 modifies NF-κB nuclear-cytoplasmic shuttling
and association with IκBα resulting in enhance nuclear
retention of activated p65 that is insensitive to inactiva-
tion by IκBα. More recently using overexpression systems
it has been suggested that IκBα can sequester HDAC1 and
HDAC3 in the cytoplasm enhancing NF-κB activity [106].Respiratory Research 2006, 7:21 http://respiratory-research.com/content/7/1/21
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Suppression of NF-κB by glucocorticoids
Glucocorticoids are 21-carbon steroid hormones [107]
which are thought to freely diffuse from the circulation
into cells across the cell membrane and bind to a cytoplas-
mic receptor (GR). Once the GR is activated, it translo-
cates to the nucleus, binds to specific DNA sequences in
the promoter regions of responsive genes and in a process
analogous to that seen with NF-κB above recruits a
number of coactivators proteins including CBP and SRC-
1 to produce a DNA-protein structure that allows
enhanced gene transcription [108]. However, despite the
ability of glucocorticoids to induce the transcription of
anti-inflammatory genes, such as annexin-1, IL-10, and
the inhibitor of NF-κB, IκBα, the major anti-inflamma-
tory effects of glucocorticoids are through repression of
inflammatory and immune genes induced by NF-κB
[109]. This interaction does not appear to alter DNA bind-
ing per se, thus treatment of asthmatic patients with high
doses of inhaled corticosteroids that suppress airway
inflammation is not associated with any reduction in NF-
κB binding to DNA [110].
The interaction between NF-κB and GR may result in dif-
fering effects on histone modifications such as acetyla-
tion/deacetylation at the activated p65 transcriptional
complex, either through GR binding to, or recruiting,
nuclear receptor corepressors such as NCoR, or interest-
ingly under some conditions by the co-activator GRIP-1,
and HDACs [96,111] or direct repression of NF-κB- asso-
ciated HAT activity [96] resulting in alterations in histone
modifications at the GM-CSF promoter in epithelial cells
[96] resulting in attenuation of gene expression. Similar
data has also been reported in primary airway smooth
muscle cells where fluticasone was able to attenuate
TNFα-induced p65 association with the native CCL11
promoter and block TNFα-induced histone H4 acetyla-
tion [112].
Using chromatin immunoprecipitation (ChIP) assays we
have demonstrated that corticosteroids reverse the
acetylation of the promoter of inflammatory genes such as
GM-CSF [96]. Other genes are not recognised through this
mechanism, so corticosteroids do not switch off genes
involved in basal cell functions, proliferation or survival.
Furthermore this explains why corticosteroids are rela-
tively safe, as side effects may be mediated mainly by gene
activation mechanisms, which requite higher concentra-
tions of corticosteroids, rather than via gene repression
and HDAC recruitment.
It has become clear that histones are not the only targets
for histone acetylases and recent evidence has suggested
that acetylation of transcription factors can modify their
activity. For example, the p65 component of NF-κB can
also be acetylated thus modifying its transcriptional activ-
ity [113]. We have recently reported that GR is also
acetylated upon ligand binding at K494 and K495 and
that deaceylation by HDAC2 is critical for interaction with
p65, at least at low concentrations of dexamethasone,
without affecting the ability of GR to associate with GREs
[113]. Furthermore, specific knockdown of HDAC2 by
RNA interference resulted in reduced sensitivity to dexam-
ethasone suppression of IL-1β-stimulated GM-CSF release
and prevented p65 association with GR. In addition, site -
directed mutagenesis of K494 and K495 reduced GR
acetylation and the ability to repress NF-κB-dependent
gene expression became insensitive to TSA. Finally, we
have shown that overexpression of HDAC2 in glucocorti-
coid insensitive alveolar macrophages from patients with
COPD is able to restore glucocorticoid sensitivity [113].
This data suggests that reduction of HDAC2 plays a critical
role in glucocorticoid insensitivity in repressing NF-κB,
but not GRE, -mediated gene expression.
HATS/HDACs in airway diseases
Little or no data is available about epigenetic marks in res-
piratory diseases probably due to a lack of research rather
During replication, parental nucleosomes are recycled and  deposited onto the two daughter strands Figure 6
During replication, parental nucleosomes are recycled and 
deposited onto the two daughter strands. In the random seg-
regation model, the parent histone octamers (red cylinders) 
are intact and pass to the two daughter strands in a random 
manner. Newly assembled nucleosomes (grey cylinders) fill in 
the gaps not occupied by the parental octamers and histone-
modifying enzymes copy the parental histone modifications 
(e.g. Acetylated groups, Ac) to newly assembled nucleo-
somes. In the semi-conservative model, the parent histone 
octamers split in half and are equally distributed among the 
two daughter strands (red halves). Nucleosome assembly 
complexes then deposit newly synthesized histones to com-
plement the existing halves of the nucleosomes (grey halves) 
present on the daughter strands. In this case, histone modify-
ing enzymes would copy the modifications (e.g. Ac) to the 
new half of the nucleosomes from the old half (symbolized by 
the green arrows).Respiratory Research 2006, 7:21 http://respiratory-research.com/content/7/1/21
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than a lack of epigenetic marks. In bronchial biopsies
from patients with asthma there is a marked increase in
HAT and a small reduction in HDAC activity compared to
normal airways [114] (Table 3). Similar changes are
found in alveolar macrophages obtained by bronchoalve-
olar lavage from patients with asthma [115]. Changes in
activity are associated with reductions in select proteins
e.g. there is a small reduction in the expression of HDAC1,
but expression of HDAC2 and 3 is normal in these cells.
Peripheral blood mononuclear cells (lymphocytes and
monocytes) appear to have normal HAT and HDAC activ-
ity, indicating that these changes occur locally in the air-
ways of asthmatic patients. Interestingly, in patients with
asthma who smoke there is a significantly greater reduc-
tion of HDAC activity in bronchial biopsies than in non-
smoking asthmatic patients (unpublished observations)
and this may account for why these smoking asthmatics
have more severe asthma and perhaps a relative steroid
insensitivity [116].
In contrast to asthma, in COPD there is no change in HAT
activity but a marked reduction in HDAC activity in the
lung parenchyma and this decrease is correlated with dis-
ease severity [117]. The reduction in HDACs in peripheral
lung and BAL macrophages is selective with a marked
reduction in HDAC2, with lesser reduction in HDAC5
and HDAC8 expression, but normal expression of the
other class 1 and 2 HDACs. Furthermore, HDAC5 expres-
sion is predominantly cytoplasmic rather than nuclear in
patients with COPD. The reduction in HDAC activity is
also related to the intensity of inflammation, as measured
by expression of IL-8 and the number of inflammatory
cells in small airways [118]. In addition, the lack of clini-
cal efficacy of corticosteroids in COPD compared with
marked effects in asthma [119-121] may be explained, at
least in part, by an inhibitory effect of cigarette smoking
and oxidative stress on HDAC function [122]. Asthmatic
patients who smoke have more severe disease and are also
resistant to the anti-inflammatory effects of corticoster-
oids [116,123]. Alveolar macrophages from normal
smokers show a reduction in HDAC activity and expres-
sion of HDAC2 (Table 3) and this is correlated with an
increase in release of TNF-α and IL-8 in response to an
inflammatory stimulus Similarly, in smoking rats there is
a reduced expression and activity of HDAC2 which is
associated with increased inflammatory gene expression
and reduced corticosteroid sensitivity [124].
In addition to subjects with COPD, patients with asthma
who smoke cigarettes also show resistance to the anti-
inflammatory actions of corticosteroids and this persists
to some extent even in ex-smokers [116,123]. Cigarette
smoking is an oxidative stress and may affect several
aspects of steroid function including effects on nuclear
cofactors [125,126]. Importantly, these effects are
reversed by antioxidants [125-127]. Intriguingly, there is
also a marked increase in oxidative stress in severe gluco-
corticoid insensitive asthma [128,129] which also shows
reduced HDAC2 expression [115]. This suggests that anti-
oxidants or NOS inhibitors, which would reduce the for-
mation of peroxynitrite, may therefore be effective thera-
pies and restore glucocorticoid responsiveness in COPD,
severe asthma and asthmatic subjects who smoke (Figure
7).
Recent evidence also suggests that changes in DNA hyper-
sensitivity related to altered methylation patterns and to
histone acetylation can occur at the IL-10 locus during T-
cell differentiation into Th2 cells and in IL-10-producing
regulatory T cells enabling optimal IL-10 gene expression
[130]. Similar results occur for other Th2 cytokines in
human cells [131].
Virus infections
Adenovirus infection increases the expression of inflam-
matory genes in epithelial cells in vitro and this appears to
be mediated via the adenoviral E1A protein, which is
capable of interacting with HAT-containing coactivators
such as CBP [132]. In COPD lungs there is evidence for
latent adenovirus infection and increased expression of
E1A protein, so that this may be a mechanism for ampli-
fication of inflammation in COPD patients [133,134].
Interestingly, adenovirus infection in guinea pigs ampli-
fies the inflammatory response to allergen [135] and is
associated with a significant reduction in HDAC activity
in the lungs in ovalbumin-sensitized animals [136]. Per-
sistence of adenovirus infections has also been implicated
in steroid-resistance in children with asthma [137]. Other
virus infections may also impair the action of HDAC2 and
thus induce steroid resistance, but this still needs to be
explored. Thus, increased gene transcription in inflamma-
Table 3: Changes in HAT and HDAC activity and protein expression in asthma and COPD.
HDAC activity HDAC 1 HDAC 2 HDAC 5 HDAC 8 HDAC 3 HAT activity
Asthma ↓↓↓ ND ND ND ↑
Smoking ↓ - ↓ ----
COPD ↓ - ↓1 ↓1 ↓1 ↓2 -
1mRNA expression also decreased compared with healthy non-smokers 2mRNA expression also decreased compared with healthy smokersRespiratory Research 2006, 7:21 http://respiratory-research.com/content/7/1/21
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tory diseases may be due to increased HAT, decreased
HDAC or a combination of both.
Lung cancer
Global hypomethylation, dysregulation of DNA methyl-
transferase and regional hypermethylation in normally
unmethylated CpG islands have all been implicated in
lung cancer [138]. Specific CpG island methylation seen
in the promoter regions of many genes associated with
neoplasias such as p16 suggests that abnormal expression
or regulation of Dnmt1 may be important in non-small
cell lung cancer (NSCLC) [139]. Methylation of the pro-
moter regions in multiple genes has been reported in ade-
nocarcinimas and NSCLC with increasing numbers of
methylated genes being associated with tumour progres-
sion [140,141]. The ability to detect these changes in
peripheral blood and sputum suggest a useful marker for
early detection and/or chemoprotective interventions
[142].
Epigenetic therapy
Since many human diseases, in particular cancer, have an
epigenetic aetiology investigators have used drugs target-
ing these processes as novel therapies [3]. Several of these
agents including histone deacetylase inhibitors (e.g.
SAHA & MS275) and DNA methylase inhibitors (e.g. 5-
azacytidine) have been tested in clinical trials with the
intention of reactivating the expression of genes that have
undergone epigenetic silencing [3]. Results, however,
have not proved as successful as predicted from cell line
data possibly as a result of cytotoxicity [143]. The proto-
type methylase inhibitors, 5-azacytidine (5-aza-CR) and
5-aza-2'-deoxycytidine (5-aza-CdR) are converted to the
deoxynucleotide triphosphates and are then incorporated
in place of cytosine into replicating DNA. They are there-
fore active only in S-phase cells, where they serve as pow-
erful mechanism-based inhibitors of DNA methylation
[3]. DNA methyltransferases get trapped on DNA contain-
ing these modified bases (e.g. azacytosine) resulting in the
formation of heritably demethylated DNA [144]. How-
ever, covalent attachment of the various DMTs to modi-
fied DNA may also be responsible for the cytotoxic effects
seen severely limiting their utility [3]. In addition, it is no
means that that the therapeutic mechanism of action of
DNA methylation and HDAC inhibitors is through epige-
netic effects. HDAC inhibitors and DNA methylation
inhibitors are cytotoxic agents and induce cell-cycle arrest
and apoptosis by upregulating p21 and/or p53 [3,145].
Furthermore, loss of genomic methylation causes p53-
dependent apoptosis, and p53 represses DNMT1, suggest-
ing a feedback loop between the two proteins [3,146].
Clinical trials with antisense oligonucleotides that target
the DNA methyltransferases are also underway [147].
We have shown that the anti-inflammatory effects of the-
ophylline with respect to resduced eosinophilia in bron-
chial biopsies from asthmatic patients may be mediated
via activation of HDAC and that this effect is independent
of PDE inhibition [148]. Theophylline appears to prefer-
entially activate class I HDACs, including HDAC2 [149].
However, the exact mechanism whereby theophylline
activates HDAC is not yet certain, but is likely to be
through signal transduction pathways, probably kinases,
that regulate HDAC activity or co-factor association. The
effects of theophylline on HDAC appear to be enhanced
under conditions of oxidative stress, making it more effi-
cient as a regulator of inflammatory genes [149]. This
means that the dose of theophylline does not have to be
increased as the disease becomes more severe as the
increase in oxidative stress would increase drug activity.
This predicts that theophylline will enhance the anti-
inflammatory actions of corticosteroids and therapeutic
concentrations of theophylline markedly potentiate the
anti-inflammatory effects of corticosteroids in vitro [149].
This may explain why adding a low dose of theophylline
is more effective than increasing the dose of inhaled corti-
costeroids in patients who are not adequately controlled
[150-152].
Summary & conclusions
The recognition that epigenetic modifications of DNA and
histones regulate inflammatory gene expression and play
a role in diverse functions such as DNA repair, prolifera-
tion, RNA interference and in several diseases indicates
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Oxidative stress can increase the expression inflammatory 
genes such as interleukin (IL)-8, matrix metalloproteinase 
(MMP) and monocyte chemotactic protein (MCP) by up-reg-
ulating NF-κB activity (a). Oxidative stress can also prevent 
glucocorticoid receptor (GR) function by (b) suppression of 
GR-associated histone deacetylase 2 (HDAC2) activity and 
expression since HDAC2 is recruited by GR to NF-κB to 
switch off inflammatory gene expression.Respiratory Research 2006, 7:21 http://respiratory-research.com/content/7/1/21
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the global importance of these effects. Their role in lung
cancer has become increasingly clear and evidence is accu-
mulating that epigenetic changes may account for some of
the heritable effects of cigarette smoking. The reversible
nature of these modifications raises the possibility of
future therapies directed against these changes.
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